Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

  • The Phase 2a trial for the treatment of NASH met its primary efficacy endpoint; PXL770-treated patients achieved statistically significant improvement in the relative decrease in liver fat mass measured by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) at 12-weeks with a greater response in patients with type 2 diabetes1

  • Key secondary measures in PXL770-treated patients included statistically significant observed improvements in liver enzymes – alanine transaminase (ALT) and hemoglobin A1c (HbA1c)

  • PXL770 was observed to be safe and well tolerated; profile supports further evaluation for combination use

  • First human clinical assessment of a direct AMPK activator; results support potential for development in NASH including key high-risk subgroups (patients with type 2 diabetes) and utility of AMPK activation in other chronic and rare metabolic diseases

  • Conference call in English scheduled today for 12:00 pm EDT (New York time) / 6 pm CEST (Paris time)

POXEL SA (Euronext: POXEL –

Read More